Direct Cellular Oximetry for Monitoring Patient Health

Jerry J. Zimmerman, PhD, MD

Faculty, Pediatric Critical Care Medicine

Seattle Children's Hospital, University of Washington School of Medicine

Despite a number of new technologies introduced over the years, there remains a major unmet need for a methodology to objectively quantify adequacy of perfusion and oxygen delivery to tissues. More specifically clinical determination and quantification of circulatory shock remains imprecise and very subjective.

Eileen M. Bulger, MD

Chief of Trauma at Harborview
Medical Center, Seattle, WA
Professor of Surgery, University of Washington School of Medicine

I am excited to see the development of the Opticyte cellular oximeter... I believe this is likely to prove a very sensitive early warning system for compensated shock.  This technology would have wide application – not only to assessment of trauma patients in the emergency department, but for monitoring of a wide variety of patients at risk for hypoperfusion in the operating room and intensive care unit.

Robert D. Guthrie, MD

System Chair of Pediatrics (retired)

Allegheny Health Network, Pittsburgh, PA

Professor of Pediatrics, College of Medicine, Drexel University

In neonatal sepsis and shock, a very high mortality rate exceeding 30% persists despite all the advances in Neonatal Intensive Care. This new medical instrument (CellSat™ 100) has the potential for detecting mild to moderate shock during the "Golden Hour" when the clinician still has the opportunity to reverse potentially fatal deterioration with current therapies.

Opticyte, Inc.

University of Washington

Box 352141

4000 Mason Road, Suite 300

Seattle, WA 98195

Phone: +1.206.775.5525

Copyright © 2019 Opticyte. All rights reserved.